1. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat
L Barbot, S Iyengar, E Cellier, R Couture Br J Pharmacol . 1999 Jun;127(3):717-28. doi: 10.1038/sj.bjp.0702620.
1. Effects of two tachykinin NK1 receptor selective agonists (septide and [Sar9, Met(O2)11]SP) were compared on the increases in mean arterial pressure (MAP), heart rate (HR) and motor behaviour following intracerebroventricular (i.c.v.) administration in unanaesthetized rat, and on the vascular permeability increases to intradermal (i.d.) injection in the anaesthetized rat. Moreover, five tachykinin NK1 receptor selective antagonists (LY303870, LY306740, LY303241, SR140333 and RP67580) were tested against the two agonists to compare their pharmacological profile. 2. [Sar9, Met(O2)11]SP and septide (10-100 pmol per rat, i.c.v.) were equipotent in increasing MAP and HR, yet they had dissimilar time-course. Both agonists increased dose-dependently face washing and sniffing while [Sar9, Met(O2)11]SP was the sole to produce grooming, septide was more potent than [Sar9, Met(O2)11]SP (6.5-650 pmol) in increasing vascular permeability. 3. For most centrally mediated responses, LY303870 and RP67580 were significantly more potent in inhibiting septide than [Sar9, Met(O2)11]SP. In some parameters, greater blockade was achieved when antagonists (particularly LY306740) were given 1 h instead of 10 min prior to i.c.v. septide. 4. All antagonists except LY303241 blocked dose-dependently the increases in vascular permeability to equipotent doses of [Sar9, Met(O2)11]SP and septide. LY303870 and LY306740 were more potent against septide. 5. The antagonism afforded by LY303870, LY306740 and LY303241 was stereoselective and only SR140333 was found to cause central and peripheral non specific effects. 6. The data confirm a distinct pharmacological profile for septide in vivo. RP67580 and LY306740 are currently the most valuable tachykinin NK1 receptor antagonists for in vivo studies in rat.
2. Spinal calmodulin inhibitors reduce N-methyl-D-aspartate- and septide-induced nociceptive behavior
L Menéndez, A Baamonde, A Hidalgo Eur J Pharmacol . 1997 Sep 17;335(1):9-14. doi: 10.1016/s0014-2999(97)01158-8.
The effect of two calmodulin inhibitors, W-7 (N-(6-aminohexyl)-5-chloro-1-naphtalenesulfonamide) and calmidazolium, on the nociceptive behavior induced by the intrathecal injection of NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-iso xazolepropionic acid) or of septide is described. Lumbar intrathecal injection of NMDA, AMPA or septide induced a caudally directed nociceptive reaction (biting, scratching and licking). The nociceptive behavior induced by NMDA (4 microg) was dose dependently inhibited when W-7 (0.25-1 micromol/rat) or calmidazolium (0.12-0.5 micromol/rat) was coinjected. Biting, scratching and licking produced by AMPA (2 microg) were unaffected by intrathecal calmodulin inhibitors. Finally, septide-evoked nociceptive behavior (2 microg) was antagonized by W-7 (0.12-0.5 micromol/rat) and calmidazolium (0.06-0.25 micromol/rat). Thus, calmodulin inhibitors prevent the nociceptive reaction evoked by drugs that modify intracellular Ca2+, NMDA and septide, without affecting the nociceptive response induced by AMPA, for which Ca2+ is not the main second messenger.
3. A "septide-sensitive" receptor is not involved in tachykinin-mediated secretory and inositol phosphate responses in rat parotid gland: are several transduction pathways involved after the stimulation of the NK1 receptor?
B Rossignol, A Berthier, C Dreux, C Huleux J Neurochem . 1998 Feb;70(2):858-64. doi: 10.1046/j.1471-4159.1998.70020858.x.
In the rat parotid gland, the neuropeptide substance P (SP), as well as SP(4-11), and septide elicited inositol phosphate production (EC50 values 0.44, 2, and 20 nM, respectively). No additivity of the maximal response to the three agonists was observed. SP, SP(4-11), and septide also stimulated protein secretion; for SP, two EC50 were determined (0.5 and 160 nM), whereas a single one could be determined for SP(4-11) and septide (EC50 values 15 and 20 nM, respectively). The selective tachykinin NK1 receptor antagonist RP67580 acted as a competitive inhibitor of both SP- and SP(4-11)-induced inositol phosphate production. Its effect on septide-induced inositol phosphate production was noncompetitive. RP67580 is apparently as potent at antagonizing septide, SP, or SP(4-11) (in all cases KB = 3 nM). These results show that in parotid gland, only NK1 receptors are activated by SP, SP(4-11), and septide. We also showed that the protein secretion stimulated by SP was inhibited competitively by RP67580, whereas the effect of RP67580 was noncompetitive on protein secretion when SP(4-11) or septide was used. Our data indicate that in rat parotid gland, the existence of a specific "septide-sensitive" receptor can be ruled out and that only the NK1 receptor is present and mediates cellular responses. Taken together, these results show that in this tissue the NK1 receptor would present at least two different binding sites that could be coupled to different transduction pathways and that would regulate protein secretion.
